Clinical trials: Liver Cirrhosis, completed
Ascites, Liver Cirrhosis
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites and the correction of hyponatraemia when used concomitantly with a standard dose regimen of spironolactone.
- Trial name
- Hypo~CAT (NCT00501722)
- Testing
- satavaptan (SR121463B)
- Where
- 13 sites in United States, Argentina and 11 more
- Volunteers
- 110 people
- Sponsor
- Sanofi
Cirrhosis With Esophageal Varices
To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.
After successful screening of patients based on inclusion criteria, we will measure the baseline Hepatic Venous Pressure Gradient.
- Trial name
- NCT02465645
- Testing
- Carvedilol, Carvedilol + Simvastatin
- Where
- India
- Volunteers
- 220 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Liver Cancer
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT01264705
- Testing
- bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Texas Southwestern Medical Center
Liver Cirrhosis, Ascites
Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis
Ascites is the most frequent complication of liver cirrhosis and carries a significant worsening of the prognosis. Approximately 10% of patients per year develop refractory ascites because of either the lack of response to…
- Trial name
- ANSWER (NCT01288794)
- Testing
- Diuretics plus human albumin, Diuretics (standard medical treatment)
- Where
- 33 sites in Italy
- Volunteers
- 431 people
- Sponsor
- University of Bologna
Hepatitis B, Liver Cirrhosis
Application of HBV Rapid Tests as a Tool for Wide-Use Screening
With over 280 000 chronic carriers, 2,500 new annual cases and 1,300 deaths each year, hepatitis B is currently a frequent and potentially severe disease in France, despite efforts towards prevention and effective care.
- Conditions
- Hepatitis B, Liver Cirrhosis, Carcinoma, Hepatocellular
- Trial name
- OPTISCREEN-B (NCT01767597)
- Testing
- ELISA testing, Rapid testing
- Where
- 5 sites in France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Decompensated Cirrhosis, Portal Hypertension
TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding
The purpose of this study is to determine whether transjugular intrahepatic portosystemic shunt (TIPS) with 10-mm covered stent is associated with lower shunt dysfunction in comparing TIPS with 8-mm covered stent in cirrhotic…
- Conditions
- Decompensated Cirrhosis, Portal Hypertension, Bleeding Varices
- Trial name
- T8/10SVB (NCT01410591)
- Testing
- 8-mm covered stent group, 10-mm covered stent group
- Where
- China
- Volunteers
- 127 people
- Sponsor
- Air Force Military Medical University, China
Hepatitis C Virus Infection
Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study
The purpose of this study was to evaluate the efficacy and safety of co-administration of glecaprevir (ABT-493)/pibrentasvir (ABT 530) plus sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV) genotype (GT) 1 …
- Trial name
- MAGELLAN-3 (NCT02939989)
- Testing
- Sofosbuvir, Glecaprevir/Pibrentasvir, Ribavirin
- Where
- 26 sites in United States, Australia and 10 more
- Volunteers
- 33 people
- Sponsor
- AbbVie
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic…
- Trial name
- TOPAZ-I (NCT02219490)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Where
- 187 sites in Algeria, Australia and 25 more
- Volunteers
- 1,596 people
- Sponsor
- AbbVie
Cirrhosis
Vitamin E Supplement in Patients With Cirrhosis and Acanthocytosis
Acanthocytes, also termed spur cell, are large erythrocytes covered with spike-like projections which are associated with severe hemolytic anemia. In advanced cirrhosis, acanthocytes may account for 20 to 30% of red blood cells.
- Trial name
- NCT01463735
- Testing
- Vitamin E supplement (tocofersolan)
- Where
- Switzerland
- Volunteers
- 27 people
- Sponsor
- University Hospital, Geneva
Liver Cirrhosis, Liver Failure
Associated Balance of Risk Score - Comprehensive Complication Index for the Prediction of Post-transplant Survival
In recent years, several scoring systems have been developed aimed at predicting early post-LT graft function. However, many of them showed poor efficacy when long-term survivals were tested.
- Conditions
- Liver Cirrhosis, Liver Failure, Liver Diseases, Transplant Failure
- Trial name
- NCT03723317
- Testing
- Liver transplantation
- Where
- Belgium
- Volunteers
- 1,782 people
- Sponsor
- European Hepatocellular Cancer Liver Transplant Group
Liver Cirrhosis
Dynamic Monitor of Portacaval Pressure Gradient
Portacaval pressure gradient (PPG) plays an important role in prediction the outcomes of cirrhotic patients undergoing TIPS. An PPG over 20 mmHg indicates a high risk of failure to control bleeding or preventing rebleeding, while…
- Trial name
- NCT03590288
- Testing
- Transjugular intrahepatic portosystemic shunt
- Where
- China
- Volunteers
- 567 people
- Sponsor
- Air Force Military Medical University, China
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Hepatitis B, Liver Cirrhosis
Entecavir for Decompensated HBV Cirrhosis
Entecavir (ETV) and tenofovir (TDF) are the first-line drugs for treatment of chronic hepatitis B virus (HBV) infection. Chronic HBV infection gradually progress to liver cirrhosis.
- Trial name
- NCT03345498
- Testing
- Entecavir
- Where
- India
- Volunteers
- 32 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
HBV, Fibrosis, Liver
Chronic Hepatitis B Virus Infection in Zambia
Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV.
- Conditions
- HBV, Fibrosis, Liver, Cirrhosis, Liver, Alcoholic Hepatitis
- Trial name
- HUTCH (NCT03158818)
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 326 people
- Sponsor
- University of Alabama at Birmingham
Hypertension, Portal
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
Study GT 026 is a Phase 2, multicenter, parallel group, North American, randomized, placebo controlled, double blind study. This study will enroll subjects with portal hypertension (HVPG greater than or equal to 6 mm Hg) who also…
- Trial name
- NASH-CX (NCT02462967)
- Testing
- GR-MD-02
- Where
- 46 sites in United States
- Volunteers
- 162 people
- Sponsor
- Galectin Therapeutics Inc.
Cirrhosis, Liver
Cirrhotics Undergoing General Surgery
Surgery on cirrhotic patients represents a clinical challenge but intervening before these patients develop complications can prolong the likelihood of these patients making it to transplant for those transplant-eligible…
- Trial name
- NCT05202457
- Testing
- Elective surgery
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Danny Lascano
Fatty Liver
Weight Management in Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is one of the most common chronic liver diseases. The cause of NASH is not completely understood and currently there is no effective treatment for this disease.
- Trial name
- NCT00266019
- Testing
- Weight Management (diet, exercise, and behavior modification)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Cirrhosis
To Compare the Safety and Efficacy of Balloon Occluded/Plug Assisted Retrograde Transvenous Obliteration With Endoscopic Variceal Obturation for Primary Prophylaxis of Gastric Varices With Large Spontaneous Shunt
Study population: All the consecutive patients of cirrhosis who are diagnosed to have large gastric varices without prior history of bleeding from GV, who came to OPD or endoscopy in Hepatology department of ILBS will be…
- Trial name
- NCT05677230
- Testing
- Balloon occluded/plug assisted retrograde transvenous obliteration., Endoscopic Variceal Obturation
- Where
- India
- Volunteers
- 56 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Liver Fibrosis
Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone
Liver cirrhosis (LC) is the final destiny in chronic liver disease. Liver transplantation is the only effective therapy available to these patients.
- Trial name
- NCT01454336
- Testing
- Cell injection
- Where
- Iran
- Volunteers
- 3 people
- Sponsor
- Royan Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.